{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?q=HER2", "query": { "q": "HER2" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1935, "total_pages": 194, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?q=HER2&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-24T04:41:48.725Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06625775", "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Metastatic Breast Cancer", "Advanced Breast Cancer", "HER2 Mutation-Related Tumors", "HER2-positive Metastatic Breast Cancer", "KRAS Mutant Metastatic Colorectal Cancer", "Metastatic Lung Cancer", "Metastatic Colorectal Cancer", "Advanced Lung Cancer", "HR-positive, HER2-negative Advanced Breast Cancer", "HER2-positive Advanced Breast Cancer" ], "interventions": [ { "name": "BBO-10203", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 392, "start_date": "2024-10-29", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-07-24T04:41:48.725Z", "location_count": 19, "location_summary": "Duarte, California • Los Angeles, California • San Diego, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06625775" }, { "nct_id": "NCT03696771", "title": "Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "NON-breast HER2+ Malignancies" ], "interventions": [ { "name": "NJH395", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-12-27", "completion_date": "2020-10-19", "has_results": false, "last_update_posted_date": "2022-02-04", "last_synced_at": "2026-07-24T04:41:48.725Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03696771" }, { "nct_id": "NCT00365365", "title": "Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Doxorubicin and cyclophosphamide (AC) + bevacizumab", "type": "DRUG" }, { "name": "Docetaxel (T) + bevacizumab", "type": "DRUG" }, { "name": "Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab", "type": "DRUG" }, { "name": "Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab", "type": "DRUG" }, { "name": "Bevacizumab and trastuzumab maintenance therapy", "type": "DRUG" }, { "name": "Bevacizumab maintenance therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 214, "start_date": "2006-08", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2012-09-14", "last_synced_at": "2026-07-24T04:41:48.725Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00365365" }, { "nct_id": "NCT05827081", "title": "Phase IIIb Study of Ribociclib + ET in Early Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Early Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Ansastrozole", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Leuprolide", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 1400, "start_date": "2024-02-28", "completion_date": "2030-09-20", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-07-24T04:41:48.725Z", "location_count": 85, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 74 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05827081" }, { "nct_id": "NCT05190445", "title": "Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-positive Gastric Cancer" ], "interventions": [ { "name": "Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel", "type": "DRUG" }, { "name": "Cinrebafusp alfa (PRS-343) in combination with tucatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pieris Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2021-11-01", "completion_date": "2023-02-01", "has_results": false, "last_update_posted_date": "2022-09-08", "last_synced_at": "2026-07-24T04:41:48.725Z", "location_count": 4, "location_summary": "Santa Barbara, California • Silver Spring, Maryland • New York, New York + 1 more", "locations": [ { "city": "Santa Barbara", "state": "California" }, { "city": "Silver Spring", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05190445" }, { "nct_id": "NCT00254592", "title": "Neoadjuvant Treatment of Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 43, "start_date": "2005-10", "completion_date": "2013-09-04", "has_results": true, "last_update_posted_date": "2019-02-28", "last_synced_at": "2026-07-24T04:41:48.725Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00254592" }, { "nct_id": "NCT05035836", "title": "A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "HER2-positive" ], "interventions": [ { "name": "Zanidatamab", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2021-11-16", "completion_date": "2028-12-29", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-07-24T04:41:48.725Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05035836" }, { "nct_id": "NCT00878709", "title": "Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "neratinib", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Puma Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 2840, "start_date": "2009-07-09", "completion_date": "2019-10-04", "has_results": true, "last_update_posted_date": "2021-06-11", "last_synced_at": "2026-07-24T04:41:48.725Z", "location_count": 185, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 147 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sedona", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00878709" }, { "nct_id": "NCT00825734", "title": "Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Sorafenib", "type": "DRUG" }, { "name": "Ixabepilone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2009-03", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2014-12-22", "last_synced_at": "2026-07-24T04:41:48.725Z", "location_count": 15, "location_summary": "Fort Myers, Florida • Terre Haute, Indiana • Louisville, Kentucky + 10 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Terre Haute", "state": "Indiana" }, { "city": "Terre Haute", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00825734" }, { "nct_id": "NCT07070232", "title": "A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "BNT326", "type": "DRUG" }, { "name": "Pumitamig", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Paroxetine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1438, "start_date": "2025-08-12", "completion_date": "2030-03", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-07-24T04:41:48.725Z", "location_count": 18, "location_summary": "Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 14 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07070232" } ] }